Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 82 entries
Sorted by: Best Match Show Resources per page
Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Sieper J, Kivitz A, van Tubergen A, Deodhar A, Szegvari B, Nurminen T, Landewé R.
PMID: 27200870
Value Health. 2014 Nov;17(7):A385-6. doi: 10.1016/j.jval.2014.08.2643. Epub 2014 Oct 26.

No abstract available.

Cite
Sieper J, Kivitz A, van Tubergen A, et al. Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study. Value Health. 2014;17(7):A385-6doi: 10.1016/j.jval.2014.08.2643.
Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Szegvari, B., Nurminen, T., & Landewé, R. (2014). Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A385-6. https://doi.org/10.1016/j.jval.2014.08.2643
Sieper, J, et al. "Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A385-6. doi: https://doi.org/10.1016/j.jval.2014.08.2643
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Szegvari B, Nurminen T, Landewé R. Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study. Value Health. 2014 Nov;17(7):A385-6. doi: 10.1016/j.jval.2014.08.2643. Epub 2014 Oct 26. PMID: 27200870.
Copy Download .nbib Format: NLM
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.

RMD open

Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D.
PMID: 28848654
RMD Open. 2017 Apr 24;3(1):e000430. doi: 10.1136/rmdopen-2017-000430. eCollection 2017.

OBJECTIVE: To report MRI outcomes and explore the relationship between clinical remission and MRI inflammation in patients with axial spondyloarthritis (axSpA) from the RAPID-axSpA trial, including radiographic (r-)axSpA and non-radiographic (nr-)axSpA.METHODS: RAPID-axSpA (NCT01087762) was double-blind and placebo-controlled to week...

Cite
Braun J, Baraliakos X, Hermann KG, et al. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017;3(1):e000430doi: 10.1136/rmdopen-2017-000430.
Braun, J., Baraliakos, X., Hermann, K. G., Landewé, R., Machado, P. M., Maksymowych, W. P., Davies, O., Hoepken, B., Nurminen, T., Stach, C., & van der Heijde, D. (2017). Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD open, 3(1), e000430. https://doi.org/10.1136/rmdopen-2017-000430
Braun, Jürgen, et al. "Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis." RMD open vol. 3,1 (2017): e000430. doi: https://doi.org/10.1136/rmdopen-2017-000430
Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017 Apr 24;3(1):e000430. doi: 10.1136/rmdopen-2017-000430. eCollection 2017. PMID: 28848654; PMCID: PMC5566980.
Copy Download .nbib Format: NLM
When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).

RMD open

Gvozdenović E, Allaart CF, van der Heijde D, Ferraccioli G, Smolen JS, Huizinga TW, Landewé R.
PMID: 27175294
RMD Open. 2016 Apr 28;2(1):e000221. doi: 10.1136/rmdopen-2015-000221. eCollection 2016.

INTRODUCTION: The European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) and the treat-to-target (T2T) principles have been developed in order to improve the treatment outcome of patients with RA, and have received broad attention....

Cite
Gvozdenović E, Allaart CF, van der Heijde D, et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open. 2016;2(1):e000221doi: 10.1136/rmdopen-2015-000221.
Gvozdenović, E., Allaart, C. F., van der Heijde, D., Ferraccioli, G., Smolen, J. S., Huizinga, T. W., & Landewé, R. (2016). When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD open, 2(1), e000221. https://doi.org/10.1136/rmdopen-2015-000221
Gvozdenović, Emilia, et al. "When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)." RMD open vol. 2,1 (2016): e000221. doi: https://doi.org/10.1136/rmdopen-2015-000221
Gvozdenović E, Allaart CF, van der Heijde D, Ferraccioli G, Smolen JS, Huizinga TW, Landewé R. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open. 2016 Apr 28;2(1):e000221. doi: 10.1136/rmdopen-2015-000221. eCollection 2016. PMID: 27175294; PMCID: PMC4860861.
Copy Download .nbib Format: NLM
Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life.

RMD open

Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A.
PMID: 30487997
RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018.

OBJECTIVE: The goal of managing axial spondyloarthritis (axSpA) is to improve and maintain patients' health-related quality of life (HRQoL), mainly through targeting towards low disease activity. Here, we aim to gain insight into the joint evolution of HRQoL and...

Cite
Imkamp M, Lima Passos V, Boonen A, et al. Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open. 2018;4(2):e000755doi: 10.1136/rmdopen-2018-000755.
Imkamp, M., Lima Passos, V., Boonen, A., Arends, S., Dougados, M., Landewé, R., Ramiro, S., Van den Bosch, F., van der Heijde, D., Wink, F. R., Spoorenberg, A., & van Tubergen, A. (2018). Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD open, 4(2), e000755. https://doi.org/10.1136/rmdopen-2018-000755
Imkamp, Maike, et al. "Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life." RMD open vol. 4,2 (2018): e000755. doi: https://doi.org/10.1136/rmdopen-2018-000755
Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A. Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open. 2018 Nov 14;4(2):e000755. doi: 10.1136/rmdopen-2018-000755. eCollection 2018. PMID: 30487997; PMCID: PMC6241970.
Copy Download .nbib Format: NLM
Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

RMD open

Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A.
PMID: 30564453
RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018.

OBJECTIVE: To investigate the occurrence of ankylosing spondylitis (AS)-related sick leave (SL) over 6 12 years and explore factors predicting first and recurrent SL.METHODS: Data from employed patients from the Outcome in Ankylosing Spondylitis International Study were used. At...

Cite
Webers C, Ramiro S, Landewé R, et al. Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open. 2018;4(2):e000766doi: 10.1136/rmdopen-2018-000766.
Webers, C., Ramiro, S., Landewé, R., van der Heijde, D., van den Bosch, F., Dougados, M., van Tubergen, A., & Boonen, A. (2018). Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD open, 4(2), e000766. https://doi.org/10.1136/rmdopen-2018-000766
Webers, Casper, et al. "Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study." RMD open vol. 4,2 (2018): e000766. doi: https://doi.org/10.1136/rmdopen-2018-000766
Webers C, Ramiro S, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A, Boonen A. Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open. 2018 Nov 27;4(2):e000766. doi: 10.1136/rmdopen-2018-000766. eCollection 2018. PMID: 30564453; PMCID: PMC6269643.
Copy Download .nbib Format: NLM
The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism

Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D.
PMID: 34489113
Semin Arthritis Rheum. 2021 Aug 01; doi: 10.1016/j.semarthrit.2021.07.021. Epub 2021 Aug 01.

BACKGROUND: The current core outcome set for ankylosing spondylitis (AS) has had only minor adaptations since its development 20 years ago. Considering the significant advances in this field during the preceding decades, an update of this core set is...

Cite
Navarro-Compán V, Boel A, Boonen A, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021;doi: 10.1016/j.semarthrit.2021.07.021.
Navarro-Compán, V., Boel, A., Boonen, A., Mease, P., Landewé, R., Kiltz, U., Dougados, M., Baraliakos, X., Bautista-Molano, W., Carlier, H., Chiowchanwisawakit, P., Dagfinrud, H., de Peyrecave, N., El-Zorkany, B., Fallon, L., Gaffney, K., Garrido-Cumbrera, M., Gensler, L. S., Haroon, N., Kwan, Y. H., Machado, P. M., Maksymowych, W. P., Poddubnyy, D., Protopopov, M., Ramiro, S., Shea, B., Song, I. H., van Weely, S., & van der Heijde, D. (2021). The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in arthritis and rheumatism, . https://doi.org/10.1016/j.semarthrit.2021.07.021
Navarro-Compán, V, et al. "The ASAS-OMERACT core domain set for axial spondyloarthritis." Seminars in arthritis and rheumatism vol. (2021). doi: https://doi.org/10.1016/j.semarthrit.2021.07.021
Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021 Aug 01; doi: 10.1016/j.semarthrit.2021.07.021. Epub 2021 Aug 01. PMID: 34489113.
Copy Download .nbib Format: NLM
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Annals of the rheumatic diseases

Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR.
PMID: 33452004
Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15.

OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure.METHODS: This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-daily oral...

Cite
Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219213.
Westhovens, R., Rigby, W. F. C., van der Heijde, D., Ching, D. W. T., Stohl, W., Kay, J., Chopra, A., Bartok, B., Matzkies, F., Yin, Z., Guo, Y., Tasset, C., Sundy, J. S., Jahreis, A., Mozaffarian, N., Messina, O. D., Landewé, R. B., Atsumi, T., & Burmester, G. R. (2021). Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens, René, et al. "Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15. PMID: 33452004; PMCID: PMC8142453.
Copy Download .nbib Format: NLM
Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?.

The Journal of rheumatology

Ferreira RJO, Landewé RBM, da Silva JAP.
PMID: 34074683
J Rheumatol. 2021 Dec;48(12):1763-1766. doi: 10.3899/jrheum.210050. Epub 2021 Jun 01.

No abstract available.

Cite
Ferreira RJO, Landewé RBM, da Silva JAP. Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. J Rheumatol. 2021;48(12):1763-1766doi: 10.3899/jrheum.210050.
Ferreira, R. J. O., Landewé, R. B. M., & da Silva, J. A. P. (2021). Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. The Journal of rheumatology, 48(12), 1763-1766. https://doi.org/10.3899/jrheum.210050
Ferreira, Ricardo J O, et al. "Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?." The Journal of rheumatology vol. 48,12 (2021): 1763-1766. doi: https://doi.org/10.3899/jrheum.210050
Ferreira RJO, Landewé RBM, da Silva JAP. Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. J Rheumatol. 2021 Dec;48(12):1763-1766. doi: 10.3899/jrheum.210050. Epub 2021 Jun 01. PMID: 34074683.
Copy Download .nbib Format: NLM
Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.

European journal of case reports in internal medicine

van Kraaij TD, Mostard RL, Ramiro S, Magro Checa C, van Dongen CM, van Haren EH, Buijs J, Landewé RB.
PMID: 32399455
Eur J Case Rep Intern Med. 2020 Apr 22;7(5):001675. doi: 10.12890/2020_001675. eCollection 2020.

Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently...

Cite
van Kraaij TD, Mostard RL, Ramiro S, et al. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. Eur J Case Rep Intern Med. 2020;7(5):001675doi: 10.12890/2020_001675.
van Kraaij, T. D., Mostard, R. L., Ramiro, S., Magro Checa, C., van Dongen, C. M., van Haren, E. H., Buijs, J., & Landewé, R. B. (2020). Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. European journal of case reports in internal medicine, 7(5), 001675. https://doi.org/10.12890/2020_001675
van Kraaij, Tom DA, et al. "Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome." European journal of case reports in internal medicine vol. 7,5 (2020): 001675. doi: https://doi.org/10.12890/2020_001675
van Kraaij TD, Mostard RL, Ramiro S, Magro Checa C, van Dongen CM, van Haren EH, Buijs J, Landewé RB. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. Eur J Case Rep Intern Med. 2020 Apr 22;7(5):001675. doi: 10.12890/2020_001675. eCollection 2020. PMID: 32399455; PMCID: PMC7213824.
Copy Download .nbib Format: NLM
COVID-19 and how evidence of a new disease evolves.

Annals of the rheumatic diseases

Kroon FPB, Mikuls TR, Landewé RB.
PMID: 32796046
Ann Rheum Dis. 2020 Aug 12; doi: 10.1136/annrheumdis-2020-218483. Epub 2020 Aug 12.

No abstract available.

Cite
Kroon FPB, Mikuls TR, Landewé RB. COVID-19 and how evidence of a new disease evolves. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218483.
Kroon, F. P. B., Mikuls, T. R., & Landewé, R. B. (2020). COVID-19 and how evidence of a new disease evolves. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218483
Kroon, Féline P B, et al. "COVID-19 and how evidence of a new disease evolves." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218483
Kroon FPB, Mikuls TR, Landewé RB. COVID-19 and how evidence of a new disease evolves. Ann Rheum Dis. 2020 Aug 12; doi: 10.1136/annrheumdis-2020-218483. Epub 2020 Aug 12. PMID: 32796046.
Copy Download .nbib Format: NLM
Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5-year data from DESIR.

Arthritis care & research

Sepriano A, Ramiro S, Landewé R, Moltó A, Claudepierre P, Wendling D, Dougados M, van der Heijde D.
PMID: 32937029
Arthritis Care Res (Hoboken). 2020 Sep 16; doi: 10.1002/acr.24449. Epub 2020 Sep 16.

OBJECTIVE: To test the impact of inflammation on MRI-structural changes occurring in the sacroiliac joints (SIJ) and the spine.METHODS: Patients with early axSpA from the DESIR cohort were included. MRIs of the SIJ (MRI-SIJ) and spine (MRI-spine), obtained at...

Cite
Sepriano A, Ramiro S, Landewé R, et al. Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5-year data from DESIR. Arthritis Care Res (Hoboken). 2020;doi: 10.1002/acr.24449.
Sepriano, A., Ramiro, S., Landewé, R., Moltó, A., Claudepierre, P., Wendling, D., Dougados, M., & van der Heijde, D. (2020). Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5-year data from DESIR. Arthritis care & research, . https://doi.org/10.1002/acr.24449
Sepriano, Alexandre, et al. "Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5-year data from DESIR." Arthritis care & research vol. (2020). doi: https://doi.org/10.1002/acr.24449
Sepriano A, Ramiro S, Landewé R, Moltó A, Claudepierre P, Wendling D, Dougados M, van der Heijde D. Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5-year data from DESIR. Arthritis Care Res (Hoboken). 2020 Sep 16; doi: 10.1002/acr.24449. Epub 2020 Sep 16. PMID: 32937029.
Copy Download .nbib Format: NLM
Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort.

Arthritis care & research

de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, van Schaardenburg DJ, van Gaalen FA, van Tubergen AM, Weel AEAM, Landewé RBM, Baeten DLP, van de Sande MGH.
PMID: 34219406
Arthritis Care Res (Hoboken). 2021 Jul 05; doi: 10.1002/acr.24743. Epub 2021 Jul 05.

OBJECTIVES: As first-degree relatives (FDRs) of HLA-B27-positive axial spondyloarthritis (axSpA) patients have an increased risk of developing axSpA, the objectives were 1) to evaluate presence of highly specific imaging features as well as clinical signs of SpA at baseline...

Cite
de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, et al. Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. Arthritis Care Res (Hoboken). 2021;doi: 10.1002/acr.24743.
de Jong, H. M. Y., de Winter, J. J. H., van der Horst-Bruinsma, I. E., van Schaardenburg, D. J., van Gaalen, F. A., van Tubergen, A. M., Weel, A. E. A. M., Landewé, R. B. M., Baeten, D. L. P., & van de Sande, M. G. H. (2021). Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. Arthritis care & research, . https://doi.org/10.1002/acr.24743
de Jong, Henriëtte M Y, et al. "Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort." Arthritis care & research vol. (2021). doi: https://doi.org/10.1002/acr.24743
de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, van Schaardenburg DJ, van Gaalen FA, van Tubergen AM, Weel AEAM, Landewé RBM, Baeten DLP, van de Sande MGH. Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. Arthritis Care Res (Hoboken). 2021 Jul 05; doi: 10.1002/acr.24743. Epub 2021 Jul 05. PMID: 34219406.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 82 entries